Robert Plenge is to take the plunge and leave his role at Merck as VP and head of translational medicine to take up a new position at Celgene to run its immunology R&D.
The news has not, however, come from an official press release from either Merck or Celgene, but rather from bio-Twitter. Last night Bruce Booth, a partner at Atlas Venture, and David Shaywitz at Forbes helped break the news.
“Exciting (if buried) news from @rplenge – he’s heading to @Celgene, great get for them, and congratulations, Robert!,” Shaywitz said, with Booth adding: “The news is out! @rplenge is newest member of R&D leadership team CELG, running immunology research. Great for Robert and for CELG!”
The news only came out when it was noticed under Plenge’s latest blog post that he added: “[Disclaimer: I am an employee of Merck, although will soon transition to a new role at Celgene.]” His Twitter bio, from which he re-tweeted Shaywitz and Booth this weekend, also now says: “soon at Celgene, ex-Merck.”
Despite the bulk of its sales coming from several cancer meds, and although it is currently only headed up in the market by its psoriasis drug Otezla (apremilast), immunology and inflammation is a core research area for Celgene.
On the horizon for this unit is ozanimod, which could yield blockbuster sales in multiple sclerosis if approved (filing is expected in that indication by year’s end at the FDA), with it also in testing for GI disorders including Crohn’s disease.
And back in January, Celgene spent $300 million upfront with $475 million in biobucks for Delinia, boosting its inflammation and immunology pipeline as it nabbed the upstart’s lead program DEL106, a new IL-2 mutein Fc fusion protein designed to preferentially upregulate regulatory T cells.
It also got its hands on “related second generation programs,” with its newly acquired early pipeline potentially targeting a variety of autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis.
Celgene did not immediately respond to a request from FierceBiotech about Plenge’s position.
By Ben Adams
Source: Fierce Biotech
Researchers at the University of Copenhagen, Denmark, have used a wireless motility capsule to reveal how changes in the gut environment impact bacteria composition and activity. The team believes the findings may help explain differences in people’s gut microbial composition and metabolism.
The approval enables the treatment of adults with moderate to severe CHE when topical corticosteroids are inadequate or inappropriate. The decision was based on the positive outcomes of the Phase III programme, which encompassed the DELTA 1 and DELTA 2 trials. The trials assessed the cream’s efficacy and safety against a cream vehicle, meeting their primary and secondary goals.
With the new plant, to be located in the Beijing Economic and Technological Development Zone, the Paris-based French drugmaker wants to significantly expand its production capacity in Asia, the company explained via the Chinese messaging service WeChat.
